

Docket No.: ATLAS-8095 US

I hereby certify that this correspondence is being deposited with the  
United States Postal Service using Express Mail Service No. EQ 580509663 US  
to: Mail Stop Amendment, Commissioner for Patents,  
PO Box 1450, Alexandria VA 22313-1450  
on 16 March 2007.

By: 

Printed: Matthew Kaser

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: BRAVEN, Helen and KEAY, Russell

Title: NUCLEIC ACID PROBES, THEIR SYNTHESIS AND USE

Serial No.: 10/506,958

Filing Date: 2<sup>nd</sup> May, 2005

Examiner: POHNERT, STEVEN C.

Group Art Unit: 1634

Mail Stop Amendment  
Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

This communication is in response to the Restriction Requirement mailed 18<sup>th</sup> October, 2006, in the above-referenced application.

Applicant respectfully petitions for a four (4)-month extension of time within which to respond to the Office Communication, dated 18<sup>th</sup> October, 2006, such extension allowing the undersigned until March 18, 2007 to respond.

Claims 1-60, 63-67, 69-71, and 75-92 were originally filed. In the Office Action, the Examiner requested Applicant to elect claims corresponding to one of the following inventions:

Group 1	Claims 1-25, 91, and 92	drawn to a method of probing nucleic acid.
Group 2	Claims 26-45	drawn to methods of detecting a specific binding protein.
Group 3	Claims 46-60 and 63-67	drawn to nucleic acid probes.
Group 4	Claims 69-71	drawn to an apparatus for measuring electrochemical properties.
Group 5	Claims 75-90	drawn to a compound with a moiety

In response to the Restriction Requirement, Applicants elect Group 1 (claims 1-25, 91, and 92) with traverse. Applicants respectfully submit that method of Group 1 (claims 1-25, 91, and 92) and the method of Group 2 (Claims 26-45) are not separate and patentably distinct. For example, the method of probing using an oligonucleotide probe to bind to a target nucleic acid sequence and electrochemically determining information (claims 1-25, 91, and 92) is substantially similar to the method of detecting using an oligonucleotide probe to bind to a specific protein and electrochemically determining information (claims 26-45). Applicants submit that examining the claims 1-25, 26-45, 91, and 92 of Examiner's groups 1 and 2 would not be an undue burden.

In addition, Applicants draw the Examiner's attention to the claims examined and granted in the equivalent European Patent Specification No. EP 1481083 B1 being the European regional phase application of the International Application No. from which the instant US national phase application is derived. The examined and granted claims of EP 1481083 B1 are equivalent to and substantially similar to claims 1-45, 91, and 92 of the instant US application.


Thus, Applicants respectfully request reconsideration of the Restriction Requirement and examination of Groups 1 and 2, claims 1-25, 26-45, 91, and 92.

Applicants also respectfully submit that claims 43, 44, and 45, are dependent upon claim 1 and therefore should be examined with claims 1-25, 91, and 92 of Examiner's Group 1. Applicants further note that new claims 93-105 are dependent upon base claim 1 and intervening claims and new claims 106-108 are dependent upon base claim 26 and intervening claims.

Please charge Deposit Account No. **50-3194** in the amount of **\$1,590.00** as set forth in the enclosed transmittal letter. However, if the USPTO determines that an additional fee is due, the Commissioner is hereby authorized to charge Bell & Associates' Deposit Account No. **50-3194**.

Respectfully submitted,

Date: 16<sup>th</sup> March 2007

  
\_\_\_\_\_  
Matthew R. Kaser, D.Phil.  
Reg. No. 44,817

416 Funston Avenue, Suite 100  
San Francisco, California 94118  
Phone: (510) 537-2040  
Fax: (415) 276-6040